Monday, January 08, 2018

sPCMA Business Forum 2018

sPCMA Business Forum 2018
March 5 & 6, 2018
Hilton Bonnet Creek | Orlando, FL

The sPCMA Business Forum covers critical industry issues and offers invaluable networking and education for individuals and companies involved in specialty drug benefit management, including PBMs and specialty pharmacies, pharma/biotech manufacturers, industry consultants, and others.

Conference sessions will cover critical issues, such as the value and net price of prescription drugs, how payers use drug pipeline data to make decisions, the value and use of digital therapeutics in patient care, the latest implications of the 21st Century Cures Act and FDAMA 114, considerations for rare and ultra-rare product development and commercialization, and much more.

Confirmed speakers include:
  • Amy Bricker, President, Supply Chain, Express Scripts
  • Laurent Carter, Vice President, Strategic Payer Marketing, U.S. Value, Access, and Payment, Bristol-Myers Squibb
  • Scott Honken, Senior Vice President, Payer Sales and Strategy, Voluntis
  • Steve Johnson, Assistant Vice President, Health Outcomes, Prime Therapeutics
  • Doug Long, Vice President, Industry Relations, IQVIA
  • Alan Lotvin, Executive Vice President, Specialty Pharmacy, CVS Health
  • Rae McMahan, Vice President & General Manager, Specialty Pharmacy, Prime Therapeutics
  • Mark Merritt, President & Chief Executive Officer, PCMA
  • Jon Roberts, Executive Vice President & Chief Operating Officer, CVS Health
  • Will Shrank, Chief Medical Officer, UPMC
  • Brian Solow, Chief Medical Officer, Optum Life Sciences
  • Caroline York, Senior Vice President, Operations, WellDoc
  • Additional speakers from Express Scripts, Magellan Rx Management, OptumRx, and others TBA

March 5 & 6, 2018
Hilton Bonnet Creek | Orlando, FL

Contact PCMA
Please contact Jenny Bradham (jbradham@pcmanet.org) with questions or to request information about the Affiliate Program or conference sponsorships.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

No comments:

Post a Comment